427 related articles for article (PubMed ID: 15296757)
1. APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo.
Liddament MT; Brown WL; Schumacher AJ; Harris RS
Curr Biol; 2004 Aug; 14(15):1385-91. PubMed ID: 15296757
[TBL] [Abstract][Full Text] [Related]
2. Endogenous origins of HIV-1 G-to-A hypermutation and restriction in the nonpermissive T cell line CEM2n.
Refsland EW; Hultquist JF; Harris RS
PLoS Pathog; 2012; 8(7):e1002800. PubMed ID: 22807680
[TBL] [Abstract][Full Text] [Related]
3. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts.
Mangeat B; Turelli P; Caron G; Friedli M; Perrin L; Trono D
Nature; 2003 Jul; 424(6944):99-103. PubMed ID: 12808466
[TBL] [Abstract][Full Text] [Related]
4. The retroviral hypermutation specificity of APOBEC3F and APOBEC3G is governed by the C-terminal DNA cytosine deaminase domain.
Haché G; Liddament MT; Harris RS
J Biol Chem; 2005 Mar; 280(12):10920-4. PubMed ID: 15647250
[TBL] [Abstract][Full Text] [Related]
5. APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription products in the absence of hypermutation. Comparisons with APOBEC3G.
Holmes RK; Koning FA; Bishop KN; Malim MH
J Biol Chem; 2007 Jan; 282(4):2587-95. PubMed ID: 17121840
[TBL] [Abstract][Full Text] [Related]
6. Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication.
Zheng YH; Irwin D; Kurosu T; Tokunaga K; Sata T; Peterlin BM
J Virol; 2004 Jun; 78(11):6073-6. PubMed ID: 15141007
[TBL] [Abstract][Full Text] [Related]
7. A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion.
Xu H; Svarovskaia ES; Barr R; Zhang Y; Khan MA; Strebel K; Pathak VK
Proc Natl Acad Sci U S A; 2004 Apr; 101(15):5652-7. PubMed ID: 15054139
[TBL] [Abstract][Full Text] [Related]
8. Comparative analysis of the antiretroviral activity of APOBEC3G and APOBEC3F from primates.
Zennou V; Bieniasz PD
Virology; 2006 May; 349(1):31-40. PubMed ID: 16460778
[TBL] [Abstract][Full Text] [Related]
9. Possible footprints of APOBEC3F and/or other APOBEC3 deaminases, but not APOBEC3G, on HIV-1 from patients with acute/early and chronic infections.
Armitage AE; Deforche K; Welch JJ; Van Laethem K; Camacho R; Rambaut A; Iversen AK
J Virol; 2014 Nov; 88(21):12882-94. PubMed ID: 25165112
[TBL] [Abstract][Full Text] [Related]
10. Population level analysis of human immunodeficiency virus type 1 hypermutation and its relationship with APOBEC3G and vif genetic variation.
Pace C; Keller J; Nolan D; James I; Gaudieri S; Moore C; Mallal S
J Virol; 2006 Sep; 80(18):9259-69. PubMed ID: 16940537
[TBL] [Abstract][Full Text] [Related]
11. The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA.
Zhang H; Yang B; Pomerantz RJ; Zhang C; Arunachalam SC; Gao L
Nature; 2003 Jul; 424(6944):94-8. PubMed ID: 12808465
[TBL] [Abstract][Full Text] [Related]
12. Guanine-adenine bias: a general property of retroid viruses that is unrelated to host-induced hypermutation.
Müller V; Bonhoeffer S
Trends Genet; 2005 May; 21(5):264-8. PubMed ID: 15851060
[TBL] [Abstract][Full Text] [Related]
13. Human retroviral host restriction factors APOBEC3G and APOBEC3F localize to mRNA processing bodies.
Wichroski MJ; Robb GB; Rana TM
PLoS Pathog; 2006 May; 2(5):e41. PubMed ID: 16699599
[TBL] [Abstract][Full Text] [Related]
14. Biochemical differentiation of APOBEC3F and APOBEC3G proteins associated with HIV-1 life cycle.
Wang X; Dolan PT; Dang Y; Zheng YH
J Biol Chem; 2007 Jan; 282(3):1585-94. PubMed ID: 17142455
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of a yeast LTR retrotransposon by human APOBEC3 cytidine deaminases.
Dutko JA; Schäfer A; Kenny AE; Cullen BR; Curcio MJ
Curr Biol; 2005 Apr; 15(7):661-6. PubMed ID: 15823539
[TBL] [Abstract][Full Text] [Related]
16. Different mutagenic potential of HIV-1 restriction factors APOBEC3G and APOBEC3F is determined by distinct single-stranded DNA scanning mechanisms.
Ara A; Love RP; Chelico L
PLoS Pathog; 2014 Mar; 10(3):e1004024. PubMed ID: 24651717
[TBL] [Abstract][Full Text] [Related]
17. Cytidine deaminases APOBEC3G and APOBEC3F interact with human immunodeficiency virus type 1 integrase and inhibit proviral DNA formation.
Luo K; Wang T; Liu B; Tian C; Xiao Z; Kappes J; Yu XF
J Virol; 2007 Jul; 81(13):7238-48. PubMed ID: 17428847
[TBL] [Abstract][Full Text] [Related]
18. Mutational comparison of the single-domained APOBEC3C and double-domained APOBEC3F/G anti-retroviral cytidine deaminases provides insight into their DNA target site specificities.
Langlois MA; Beale RC; Conticello SG; Neuberger MS
Nucleic Acids Res; 2005; 33(6):1913-23. PubMed ID: 15809227
[TBL] [Abstract][Full Text] [Related]
19. Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F.
Russell RA; Pathak VK
J Virol; 2007 Aug; 81(15):8201-10. PubMed ID: 17522216
[TBL] [Abstract][Full Text] [Related]
20. Antiviral potency of APOBEC proteins does not correlate with cytidine deamination.
Bishop KN; Holmes RK; Malim MH
J Virol; 2006 Sep; 80(17):8450-8. PubMed ID: 16912295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]